Target intelligence / Profile preview

Solute carrier family 2, facilitated glucose transporter member 5 (SLC2A5)

Target
SLC2A5
Molecular classification
Transporter
01

Overview

Solute carrier family 2, facilitated glucose transporter member 5 (SLC2A5), commonly known as GLUT5, is a member of the major facilitator superfamily that functions as a highly specific facilitative fructose transporter. It is primarily expressed in the apical membrane of enterocytes in the small intestine, where it mediates dietary fructose absorption, as well as in the kidneys, skeletal muscle, and microglia. While physiologically essential for fructose uptake and metabolic homeostasis, SLC2A5 is frequently upregulated in various malignancies, including breast, colorectal, and lung cancers, where it supports tumor cell proliferation, migration, and metastasis by fueling the fructose-tumor feeding axis.

Consequently, SLC2A5 has emerged as an attractive therapeutic target in oncology and metabolic diseases like non-alcoholic fatty liver disease (NAFLD) and obesity. Pharmacological targeting of SLC2A5 involves small-molecule inhibitors such as MSNBA and the clinical candidate S-700, which aim to block fructose uptake and disrupt cancer cell metabolism or alleviate metabolic syndrome. However, therapeutic challenges include avoiding off-target inhibition of other glucose transporters (like GLUT1 or GLUT4) and managing potential gastrointestinal side effects resembling fructose malabsorption.

Other names
GLUT5GLUT-5Glucose transporter type 5Fructose transporterSolute carrier family 2 member 5
02

Mechanism of action

Inhibition of facilitative fructose transport across the cell membrane, either through competitive binding at the active site, allosteric modulation, or transcriptional downregulation of transporter expression.

03

Biological functions

Fructose transportDietary fructose absorptionMetabolic regulationBlood pressure regulation
04

Disease associations

CancerMetabolic syndromeFructose malabsorptionNonalcoholic fatty liver diseaseObesityDiabetesAcute ischemic stroke
05

Safety considerations

Fructose malabsorptionGastrointestinal distress (bloating, cramps, diarrhea)Off-target inhibition of other GLUT transporters (e.g., GLUT1, GLUT4) leading to impaired glucose homeostasisAltered systemic blood pressure regulation
06

Interacting drugs

MSNBA

7 more in the full profile.

07

Biomarkers

SLC2A5 mRNA expressionGLUT5 protein expressionSerum GLUT5 levelsFructose uptake rate

Beyond the preview

Go deeper on Solute carrier family 2, facilitated glucose transporter member 5 (SLC2A5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 2, facilitated glucose transporter member 5 (SLC2A5).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call